Welcome

Oncopeptides invites investors, analysts and media to an online Capital Markets Update live from Stockholm on 13 November 2025, at 9:00 CET

Focus of the event will be to inform the market about the current state and future potential of Oncopeptides' research.

Leading medical experts from across the world will provide their perspective on the current multiple myeloma landscape and how Oncopeptides' current and future drugs have a place in it.

Participants will also hear from the company´s ownership and management, discussing the future of Oncopeptides.

The half-day program will feature presentations and discussions featuring a distinguished group of international experts, providing clinical, scientific, and market perspectives from Europe, Japan, and the U.S.

Highlights include:

· Prof. Dr. Sebastian Theurich, LMU University Hospital Munich
– “Multiple Myeloma and the Unmet Medical Need.”

· Dr. María-Victoria Mateos, University of Salamanca
– “Clinical reflections on real-world experience with Pepaxti.”

· Dr. Claudio Cerchione, IRST IRCCS Italy, and Prof. Dr. med. Klaus Fenchel, Germany
– “Panel discussion on the European treatment landscape and real-world evidence.”

· Prof. Shinsuke Iida, Nagoya City University (Japan)
– “The Japanese multiple myeloma landscape.”

· Prof. Paul G. Richardson, Dana-Farber Cancer Institute / Harvard Medical School (U.S.)
– “The potential of the PDC platform in the U.S. market.”

The event will also feature presentations from Oncopeptides CEO Sofia Heigis and Dr. Björn Odlander, Founder & Managing Partner of HealthCap, providing insights into Oncopeptides’ business outlook, growth strategy, and investment case.

Click here for full agenda

Please register

The live broadcast starts on 05 November 2026 at 08:00 UTC

Speakers

Sofia Heigis

Henrik Bergentoft